Exicure (XCUR) said its subsidiary, GPCR Therapeutics USA, dosed the 19th patient in an ongoing phase 2 clinical trial of a small molecule inhibitor in multiple myeloma patients undergoing autologous stem cell transplant.

The trial is expected to finish patient recruitment at the end of April.

The study is a multi-center trial evaluating the safety and efficacy of the CXCR4 inhibitor, GPC-100 (burixafor), and propranolol in combination with G-CSF, the company said late Monday.

It said the study's preliminary results are encouraging as 100% of patients achieved the primary endpoint of successful stem cell mobilization.